Turning Natural Variation into Product Innovation and Sustainable Growth
Fibriant leverages its expertise in fibrinogen technology to develop innovative healthcare solutions based on specific, naturally occurring, variants of human fibrinogen. Human fibrinogen plays a pivotal role in blood clotting, tissue repair and host defense against pathogens. The company has developed a pilot manufacturing process for recombinant production of different fibrinogen variants and has demonstrated pre-clinical proof of concept for specific fibrinogen variants as topical hemostat and as anti-virulence factor in staphylococcus aureus infections. Fibriant executes a hybrid business model focused on sustainable growth and is led by a team with extensive scientific, product development and business experience.
Speaker: Jaap Koopman, Founder and CEO
Jaap Koopman has over 35 years of experience in bio-medical R & D, of which 20 years in the biotech industry. In 2004 he founded ProFibrix BV and led this company as CEO through multiple venture finance rounds. As CSO he supported the development of a dry powder fibrin sealant product to approval in US and EU and was part of the management team that led the acquisition of ProFibrix BV by The Medicine Company in August 2013. In 2015 Jaap founded Fibriant BV, that is focussed on development of a recombinant fibrinogen technology platform, and currently is the CEO of this company.
Designers and artists: present your creative healthcare solution or prototype to key players in Health & Life Sciences on 13 February 2020 at I4H conference in De Doelen ICC in Rotterdam for FREE with the I4H Design Expo! This unique opportunity will allow you to generate valuable contacts with potential collaborators, business partners and investors in the healthcare sector. Apply before 15 December. More information
Pitch your company
Are you looking for funding, partnerships and/or exposure to take your venture and innovation to the next stage? Then seize the opportunity to pitch your company at Innovation for Health & Global Investor Forum on 12-13 February 2020 to decision makers in Health & Life sciences sector. We have room for pitches from 10 biotech, 10 medtech and 10 digital health companies. More information
Contribute to I4H2020
Do you want to capture the attention of our 800+ high-level attendees in key positions? Contribute to the 7th edition of Innovation for Health on 13 February 2020 and benefit from the diverse sponsorship, exhibition and speaking opportunities that this conference has to offer you! Contact us for all opportunities